Nanopublications LDF server

Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }

• LinguisticSystem label "python" assertion.
• out1 label "out1" assertion.
• image label "image" assertion.
• ReferredMentioning label "identifier of a thing mentioned in the object that is reviewed" assertion.
• comment label "This comment" assertion.
• PositivityClass label "specify whether it is positive, neutral, or negative" assertion.
• ActionClass label "specify whether an action is required" assertion.
• ActionClass label "specify whether it is about syntax, style, or content" assertion.
• reviewComment label "The content of this comment as free text" assertion.
• impact label "integer value from 1 (low impact) to 5 (high impact)" assertion.
• ReferredObject label "identifier of the object that is reviewed (e.g. a text or nanopublication)" assertion.
• assertion label "Making a review comment according to the LinkFlows model" assertion.
• img label "img" assertion.
• step label "Convert the RGB color image to grayscale" assertion.
• LinguisticSystem label "python" assertion.
• out1 label "out1" assertion.
• step label "Apply a Gaussian blur to the negative from step 2" assertion.
• LinguisticSystem label "python" assertion.
• img label "img" assertion.
• out1 label "out1" assertion.
• factor label "factor" assertion.
• out1 label "out1" assertion.
• LinguisticSystem label "python" assertion.
• step label "Adjust the constrast of the final image" assertion.
• img label "img" assertion.
• out1 label "out1" assertion.
• img label "img" assertion.
• out1 label "out1" assertion.
• img label "img" assertion.
• association label "fosphenytoin sodium injection usp is indicated for the treatment of generalized tonic clonic status epilepticus and prevention and treatment of seizures occurring during neurosurgery fosphenytoin sodium injection usp can also be substituted short term for oral phenytoin fosphenytoin sodium injection usp should be used only when oral phenytoin administration is not possible see dosage and administration 2 4 precautions 5 2 fosphenytoin sodium injection usp is indicated for the treatment of generalized tonic clonic status epilepticus and prevention and treatment of seizures occurring during neurosurgery fosphenytoin sodium injection usp can also be substituted as short term use for oral phenytoin fosphenytoin sodium injection usp should be used only when oral phenytoin administration is not possible 1" assertion.
• association label "matzim la diltiazem hydrochloride extended release tablets are a nondihydropyridine calcium channel blocker indicated for treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions it can be used alone or in combination with other antihypertensives 1 1 improving exercise tolerance in patients with chronic stable angina 1 2 matzim la diltiazem hydrochloride extended release tablets are indicated for the treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug control of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than one drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education program s joint national committee on prevention detection evaluation and treatment of high blood pressure jnc numerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly elevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal some antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects e g on angina heart failure or diabetic kidney disease these considerations may guide selection of therapy matzim la diltiazem hydrochloride extended release tablets may be used alone or in combination with other antihypertensive medications matzim la diltiazem hydrochloride extended release tablets are indicated to improve exercise tolerance in patients with chronic stable angina" assertion.
• association label "modafinil tablets are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy obstructive sleep apnea and shift work disorder in osa modafinil tablets are indicated as an adjunct to standard treatment s for the underlying obstruction if continuous positive airway pressure cpap is the treatment of choice for a patient a maximal effort to treat with cpap for an adequate period of time should be made prior to initiating modafinil tablets if modafinil tablets are used adjunctively with cpap the encouragement of and periodic assessment of cpap compliance is necessary in all cases careful attention to the diagnosis and treatment of the underlying sleep disorder s is of utmost importance prescribers should be aware that some patients may have more than one sleep disorder contributing to their excessive sleepiness the effectiveness of modafinil in long term use greater than 9 weeks in narcolepsy clinical trials and 12 weeks in osa and swd clinical trials has not been systematically evaluated in placebo controlled trials the physician who elects to prescribe modafinil tablets for an extended time in patients with narcolepsy osa or swd should periodically reevaluate long term usefulness for the individual patient" assertion.
• association label "leflunomide is indicated in adults for the treatment of active rheumatoid arthritis ra to reduce signs and symptoms to inhibit structural damage as evidenced by x ray erosions and joint space narrowing to improve physical function see clinical studies aspirin nonsteroidal anti inflammatory agents and or low dose corticosteroids may be continued during treatment with leflunomide see precautions drug interactions nsaids warnings immunosuppression potential bone marrow suppression" assertion.
• association label "a intravenous or intramuscular administration when oral therapy is not feasible and the strength dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition those products labeled for intravenous or intramuscular use are indicated as follows 1 endocrine disorders primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the drug of choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance acute adrenocortical insufficiency hydrocortisone or cortisone is the drug of choice mineralocorticoid supplementation may be necessary particularly when synthetic analogs are used preoperatively and in the event of serious trauma or illness in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2 rheumatic disorders as adjunctive therapy for short term administration to tide the patient over an acute episode or exacerbation in post traumatic osteoarthritis synovitis of osteoarthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require low dose maintenance therapy acute and subacute bursitis epicondylitis acute nonspecific tenosynovitis acute gouty arthritis psoriatic arthritis ankylosing spondylitis 3 collagen diseases during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus acute rheumatic carditis 4 dermatologic diseases pemphigus severe erythema multiforme stevens johnson syndrome exfoliative dermatitis bullous dermatitis herpetiformis severe seborrheic dermatitis severe psoriasis mycosis fungoides 5 allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in bronchial asthma contact dermatitis atopic dermatitis serum sickness seasonal or perennial allergic rhinitis drug hypersensitivity reactions urticarial transfusion reactions acute noninfectious laryngeal edema epinephrine is the drug of first choice 6 ophthalmic diseases severe acute and chronic allergic and inflammatory processes involving the eye such as herpes zoster ophthalmicus iritis iridocyclitis chorioretinitis diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia anterior segment inflammation allergic conjunctivitis allergic corneal marginal ulcers keratitis 7 gastrointestinal diseases to tide the patient over a critical period of the disease in ulcerative colitis systemic therapy regional enteritis systemic therapy 8 respiratory diseases symptomatic sarcoidosis berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate anti tuberculosis chemotherapy loeffler s syndrome not manageable by other means aspiration pneumonitis 9 hematologic disorders acquired autoimmune hemolytic anemia idiopathic thrombocytopenic purpura in adults i v only i m administration is contraindicated secondary thrombocytopenia in adults erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia 1 neoplastic diseases for palliative management of leukemias and lymphomas in adults acute leukemic of childhood 11 edematous states to induce diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus 12 nervous system acute exacerbations of multiple sclerosis 13 miscellaneous tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate anti tuberculosis chemotherapy trichinosis with neurologic or myocardial involvement diagnostic testing of adrenocortical hyperfunction cerebral edema of diverse etiologies in conjunction with adequate neurological evaluation and management b intra articular or soft tissue administration when the strength and dosage form of the drug lend the preparation to the treatment of the condition those products labeled for intra articular or soft tissue administration are indicated as adjunctive therapy for short term administration to tide the patient over an acute episode or exacerbation in synovitis of osteoarthritis rheumatoid arthritis acute and subacute bursitis acute gouty arthritis epicondylitis acute nonspecific tenosynovitis post traumatic osteoarthritis c intralesional administration when the strength and dosage form of the drug lend the preparation to the treatment of the condition those products labeled for intralesional administration are indicated for keloids localized hypertrophic infiltrated inflammatory lesions of lichen planus psoriatic plaques granuloma annulare and lichen simplex chronicus neurodermatitis discoid lupus erythematosus necrobiosis lipoidica diabeticorum alopecia areata they also may be useful in cystic tumors of an aponeurosis tendon ganglia" assertion.
• association label "cystadane is a methylating agent indicated for the treatment of homocystinuria to decrease elevated homocysteine blood levels included within the category of homocystinuria are 1 cystathionine beta synthase cbs deficiency 5 1 methylenetetrahydrofolate reductase mthfr deficiency cobalamin cofactor metabolism cbl defect cystadane r betaine anhydrous for oral solution is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood levels included within the category of homocystinuria are cystathionine beta synthase cbs deficiency 5 1 methylenetetrahydrofolate reductase mthfr deficiency cobalamin cofactor metabolism cbl defect" assertion.
• association label "probenecid tablets are indicated for the treatment of the hyperuricemia associated with gout and gouty arthritis as an adjuvant to therapy with penicillin or with ampicillin methicillin oxacillin cloxacillin or nafcillin for elevation and prolongation of plasma levels by whatever route the antibiotic is given" assertion.
• association label "erlotinib tablets are a kinase inhibitor indicated for the treatment of patients with metastatic non small cell lung cancer nsclc whose tumors have epidermal growth factor receptor egfr exon 19 deletions or exon 21 l858r substitution mutations as detected by an fda approved test receiving first line maintenance or second or greater line treatment after progression following at least one prior chemotherapy regimen 1 1 first line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer in combination with gemcitabine 1 2 limitations of use safety and efficacy of erlotinib tablets have not been established in patients with nsclc whose tumors have other egfr mutations 1 1 erlotinib tablets are not recommended for use in combination with platinum based chemotherapy 1 1 erlotinib tablets are indicated for the treatment of patients with metastatic non small cell lung cancer nsclc whose tumors have epidermal growth factor receptor egfr exon 19 deletions or exon 21 l858r substitution mutations as detected by an fda approved test receiving first line maintenance or second or greater line treatment after progression following at least one prior chemotherapy regimen see clinical studies 14 1 14 3 safety and efficacy of erlotinib tablets have not been established in patients with nsclc whose tumors have other egfr mutations see clinical studies 14 1 14 2 erlotinib tablets are not recommended for use in combination with platinum based chemotherapy see clinical studies 14 4 erlotinib tablets in combination with gemcitabine is indicated for the first line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer see clinical studies 14 5" assertion.
• association label "altabax r 2 staphylococcus aureus streptococcus pyogenes see clinical studies 14 to reduce the development of drug resistant bacteria and maintain the effectiveness of altabax and other antibacterial drugs altabax should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria altabax a pleuromutilin antibacterial is indicated for the topical treatment of impetigo due to staphylococcus aureus streptococcus pyogenes 1" assertion.
• association label "prednisone tablets are indicated in the following conditions 1 endocrine disorders primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2 rheumatic disorders as adjunctive therapy for short term administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require low dose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post traumatic osteoarthritis synovitis of osteoarthritis epicondylitis 3 collagen diseases during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis 4 dermatologic diseases pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevens johnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis 5 allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis bronchial asthma contact dermatitis atopic dermatitis serum sickness drug hypersensitivity reactions 6 ophthalmic diseases severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic corneal marginal ulcers herpes zoster ophthalmicus anterior segment inflammation diffuse posterior uveitis and choroiditis sympathetic ophthalmia allergic conjunctivitis keratitis chorioretinitis optic neuritis iritis and iridocyclitis 7 respiratory diseases symptomatic sarcoidosis loeffler s syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis 8 hematologic disorders idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia 9 neoplastic diseases for palliative management of leukemias and lymphomas in adults acute leukemia of childhood 1 edematous states to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus 11 gastrointestinal diseases to tide the patient over a critical period of the disease in ulcerative colitis regional enteritis 12 nervous system acute exacerbations of multiple sclerosis 13 miscellaneous tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement" assertion.
• association label "heparin sodium injection is indicated for prophylaxis and treatment of venous thrombosis and pulmonary embolism prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who for other reasons are at risk of developing thromboembolic disease atrial fibrillation with embolization treatment of acute and chronic consumptive coagulopathies disseminated intravascular coagulation prevention of clotting in arterial and cardiac surgery prophylaxis and treatment of peripheral arterial embolism anticoagulant use in blood transfusions extracorporeal circulation and dialysis procedures heparin sodium injection is an anticoagulant indicated for 1 prophylaxis and treatment of venous thrombosis and pulmonary embolism prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who for other reasons are at risk of developing thromboembolic disease atrial fibrillation with embolization treatment of acute and chronic consumptive coagulopathies disseminated intravascular coagulation prevention of clotting in arterial and cardiac surgery prophylaxis and treatment of peripheral arterial embolism use as an anticoagulant in blood transfusions extracorporeal circulation and dialysis procedures" assertion.
• association label "hydrocortisone tablets usp are indicated in the following conditions endocrine disorders primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer rheumatic disorders as adjunctive therapy for short term administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require low dose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post traumatic osteoarthritis synovitis of osteoarthritis epicondylitis collagen diseases during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis dermatologic diseases pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevens johnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions ophthalmic diseases severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia respiratory diseases symptomatic sarcoidosis loeffler s syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis hematologic disorders idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia neoplastic diseases for palliative management of leukemias and lymphomas in adults acute leukemia of childhood edematous states to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus gastrointestinal diseases to tide the patient over a critical period of the disease in ulcerative colitis regional enteritis nervous system acute exacerbations of multiple sclerosis miscellaneous tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement" assertion.
• association label "famciclovir tablets a prodrug of penciclovir is a nucleoside analog dna polymerase inhibitor indicated for immunocompetent adult patients 1 1 herpes labialis cold sores treatment of recurrent episodes genital herpes treatment of recurrent episodes suppressive therapy of recurrent episodes herpes zoster shingles hiv infected adult patients 1 2 treatment of recurrent episodes of orolabial or genital herpes limitation of use 1 3 the efficacy and safety of famciclovir tablets has not been established for patients 18 years of age immunocompromised patients other than for the treatment of recurrent episodes of orolabial or genital herpes in hiv infected patients black and african american patients with recurrent genital herpes herpes labialis cold sores genital herpes recurrent episodes suppressive therapy herpes zoster shingles recurrent orolabial or genital herpes the efficacy and safety of famciclovir tablets have not been established for patients 18 years of age patients with first episode of genital herpes patients with ophthalmic zoster immunocompromised patients other than for the treatment of recurrent orolabial or genital herpes in hiv infected patients black and african american patients with recurrent genital herpes" assertion.
• association label "relenza an influenza virus neuraminidase inhibitor nai is indicated for treatment of acute uncomplicated influenza type a and b infections 1 1 prophylaxis of influenza 1 2 important limitations of use not recommended for treatment or prophylaxis of influenza in 5 1 not proven effective for 1 3 1 3 not a substitute for annual influenza vaccination 1 3 consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use relenza 1 3 relenza zanamivir inhalation powder is indicated for treatment of uncomplicated acute illness due to influenza a and b virus in adults and pediatric patients aged 7 years and older who have been symptomatic for no more than 2 days relenza is indicated for prophylaxis of influenza in adults and pediatric patients aged 5 years and older see warnings and precautions 5 1" assertion.
• association label "acitretin capsules usp are indicated for the treatment of severe psoriasis in adults because of significant adverse effects associated with its use acitretin capsules usp should be prescribed only by those knowledgeable in the systemic use of retinoids in females of reproductive potential acitretin capsules usp should be reserved for non pregnant patients who are unresponsive to other therapies or whose clinical condition contraindicates the use of other treatments see boxed contraindications and warnings most patients experience relapse of psoriasis after discontinuing therapy subsequent courses when clinically indicated have produced efficacy results similar to the initial course of therapy" assertion.
• association label "captopril tablets usp are indicated for the treatment of hypertension hypertension in using captopril consideration should be given to the risk of neutropenia agranulocytosis see warnings captopril may be used as initial therapy for patients with normal renal function in whom the risk is relatively low in patients with impaired renal function particularly those with collagen vascular disease captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs or have failed to respond satisfactorily to drug combinations captopril is effective alone and in combination with other antihypertensive agents especially thiazide type diuretics the blood pressure lowering effects of captopril and thiazides are approximately additive captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis the beneficial effect of captopril in heart failure does not require the presence of digitalis however most controlled clinical trial experience with captopril has been in patients receiving digitalis as well as diuretic treatment heart failure captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction 4 and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients left ventricular dysfunction after myocardial infarction captopril tablets are indicated for the treatment of diabetic nephropathy proteinuria 5 mg day in patients with type i insulin dependent diabetes mellitus and retinopathy captopril tablets decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes death or need for renal transplantation or dialysis diabetic nephropathy in considering use of captopril tablets it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in non blacks in addition ace inhibitors for which adequate data are available cause a higher rate of angioedema in black than in non black patients see warnings angioedema" assertion.
• association label "prostin vr pediatric sterile solution is indicated for palliative not definitive therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival such congenital heart defects include pulmonary atresia pulmonary stenosis tricuspid atresia tetralogy of fallot interruption of the aortic arch coarctation of the aorta or transposition of the great vessels with or without other defects in infants with restricted pulmonary blood flow the increase in blood oxygenation is inversely proportional to pretreatment po 2 2 2 prostin vr pediatric should be administered only by trained personnel in facilities that provide pediatric intensive care" assertion.
• association label "to reduce the development of drug resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below rocky mountain spotted fever typhus fever and the typhus group q fever rickettsialpox and tick fevers caused by rickettsiae respiratory tract infections caused by lymphogranuloma venereum due to psittacosis ornithosis due to trachoma due to although the infectious agent is not always eliminated as judged by immunofluorescence inclusion conjunctivitis caused by nongonococcal urethritis in adults caused by or relapsing fever due to chancroid caused by plague due to tularemia due to cholera caused by campylobacter fetus infections caused by brucellosis due to species in conjunction with streptomycin bartonellosis due to granuloma inguinale caused by demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug species species respiratory tract infections caused by respiratory tract and urinary tract infections caused by species demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug upper respiratory infections caused by pneumoniae skin and skin structure infections caused by note tetracyclines including demeclocycline are not the drugs of choice in the treatment of any type of staphylococcal infection when penicillin is contraindicated tetracyclines including demeclocycline hydrochloride are alternative drugs in the treatment of the following infections uncomplicated urethritis in men due to and for the treatment of other uncomplicated gonococcal infections infections in women caused by syphilis caused by subspecies yaws caused by subspecies listeriosis due to anthrax due to vincent s infection caused by actinomycosis caused by clostridial diseases caused by species in acute intestinal amebiasis demeclocycline hydrochloride may be a useful adjunct to amebicides in severe acne demeclocycline hydrochloride may be a useful adjunctive therapy mycoplasma pneumoniae chlamydia trachomatis chlamydia psittaci chlamydia trachomatis chlamydia trachomatis ureaplasma urealyticum chlamydia trachomatis borrelia recurrentis haemophilus ducreyi yersinia pestis francisella tularensis vibrio cholerae campylobacter fetus brucella bartonella bacilliformis calymmatobacterium granulomatis escherichia coli enterobacter aerogenes shigella acinetobacter haemophilus influenzae klebsiella streptococcus staphylococcus aureus neisseria gonorrhoeae neisseria gonorrhoeae treponema pallidum pallidum treponema pallidum pertenue listeria monocytogenes bacillus anthracis fusobacterium fusiforme actinomyces israelii clostridium" assertion.
• obesity-with-metabolic-abnormality label "obesity with metabolic abnormality" assertion.
• nanopub label "add the URI of the nanopublication here" assertion.
• assertion label "Submitting a formalization paper to the Data Science special issue 2021" assertion.
• DataScienceSpecialIssue label "Formalization Papers Special Issue 2021 at Data Science" assertion.
• DataScienceSpecialIssue label "Formalization Papers Special Issue 2021 at Data Science" assertion.
• DataScienceSpecialIssue label "Formalization Papers Special Issue 2021 at Data Science" assertion.
• DataScienceSpecialIssue label "Formalization Papers Special Issue 2021 at Data Science" assertion.
• DataScienceSpecialIssue label "Formalization Papers Special Issue 2021 at Data Science" assertion.
• DataScienceSpecialIssue label "Formalization Papers Special Issue 2021 at Data Science" assertion.
• partOf label "is a part of" assertion.
• partOf label "is submitted as part of" assertion.
• partOf label "is submitted as part of" assertion.
• partOf label "is submitted as part of" assertion.
• partOf label "is submitted as part of" assertion.
• partOf label "is submitted as part of" assertion.
• partOf label "is submitted as part of" assertion.
• partOf label "is submitted as part of" assertion.
• partOf label "is submitted as part of" assertion.
• withStatus label "has the status" assertion.
• withStatus label "has the status" assertion.
• withStatus label "has the status" assertion.
• withStatus label "has the status" assertion.
• withStatus label "has the status" assertion.
• withStatus label "has the status" assertion.
• withStatus label "has the status" assertion.
• withStatus label "has the status" assertion.
• withStatus label "has the status" assertion.
• submitted label "submitted" assertion.
• submitted label "submitted" assertion.
• submitted label "submitted" assertion.
• association label "famotidine is indicated in most adult patients heal within 4 weeks there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks short term treatment of active duodenal ulcer controlled studies in adults have not extended beyond one year maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer most adult patients heal within 6 weeks studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks short term treatment of active benign gastric ulcer famotidine is indicated for short term treatment of patients with symptoms of gerd see famotidine is also indicated for the short term treatment of esophagitis due to gerd including erosive or ulcerative disease diagnosed by endoscopy see short term treatment of gastroesophageal reflux disease gerd clinical pharmacology in adults clinical studies clinical pharmacology in adults clinical studies treatment of pathological hypersecretory conditions e g zollinger ellison syndrome multiple endocrine adenomas see clinical pharmacology in adults clinical studies" assertion.
• association label "hydrocortisone tablets usp are indicated in the following conditions endocrine disorders primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer rheumatic disorders as adjunctive therapy for short term administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require low dose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post traumatic osteoarthritis synovitis of osteoarthritis epicondylitis collagen diseases during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis dermatologic diseases pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevens johnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions ophthalmic diseases severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia respiratory diseases symptomatic sarcoidosis loeffler s syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis hematologic disorders idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia neoplastic diseases for palliative management of leukemias and lymphomas in adults acute leukemia of childhood edematous states to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus gastrointestinal diseases to tide the patient over a critical period of the disease in ulcerative colitis regional enteritis nervous system acute exacerbations of multiple sclerosis miscellaneous tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement" assertion.
• association label "mebendazole tablets are indicated for the treatment of enterobius vermicularis trichuris trichiura ascaris lumbricoides ancylostoma duodenale necator americanus efficacy varies as a function of such factors as preexisting diarrhea and gastrointestinal transit time degree of infection and helminth strains efficacy rates derived from various studies are shown in the table below pinworm enterobiasis whipworm trichuriasis common roundworm ascariasis hookworm cure rates 95 68 98 96 egg reduction 93 99 99" assertion.
• association label "vexol r 1 rimexolone ophthalmic suspension is indicated for the treatment of postoperative inflammation following ocular surgery and in the treatment of anterior uveitis" assertion.
• association label "pamidronate disodium for injection usp in conjunction with adequate hydration is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy with or without bone metastases patients who have either epidermoid or non epidermoid tumors respond to treatment with pamidronate disodium for injection usp vigorous saline hydration an integral part of hypercalcemia therapy should be initiated promptly and an attempt should be made to restore the urine output to about 2 l day throughout treatment mild or asymptomatic hypercalcemia may be treated with conservative measures i e saline hydration with or without loop diuretics patients should be hydrated adequately throughout the treatment but overhydration especially in those patients who have cardiac failure must be avoided diuretic therapy should not be employed prior to correction of hypovolemia the safety and efficacy of pamidronate disodium for injection usp in the treatment of hypercalcemia associated with hyperparathyroidism or with other non tumor related conditions has not been established pamidronate disodium for injection usp is indicated for the treatment of patients with moderate to severe paget s disease of bone the effectiveness of pamidronate disodium for injection usp was demonstrated primarily in patients with serum alkaline phosphatase 3 times the upper limit of normal pamidronate disodium for injection usp therapy in patients with paget s disease has been effective in reducing serum alkaline phosphatase and urinary hydroxyproline levels by 5 in at least 5 of patients and by 3 in at least 8 of patients pamidronate disodium for injection usp therapy has also been effective in reducing these biochemical markers in patients with paget s disease who failed to respond or no longer responded to other treatments pamidronate disodium for injection usp is indicated in conjunction with standard antineoplastic therapy for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma the pamidronate disodium for injection usp treatment effect appeared to be smaller in the study of breast cancer patients receiving hormonal therapy than in the study of those receiving chemotherapy however overall evidence of clinical benefit has been demonstrated see clinical pharmacology osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma clinical trials" assertion.
• association label "prednisolone sodium phosphate oral solution 15 mg prednisolone per 5 ml is indicated in the following conditions 1 allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with seasonal or perennial allergic rhinitis asthma contact dermatitis atopic dermatitis serum sickness drug hypersensitivity reactions 2 dermatologic diseases pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevens johnson syndrome exfoliative erythroderma mycosis fungoides 3 edematous states to induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations with idiopathic nephrotic syndrome without uremia 4 endocrine disorders primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditis 5 gastrointestinal diseases to tide the patient over a critical period of the disease in ulcerative colitis regional enteritis 6 hematologic disorders idiopathic thrombocytopenic purpura in adults selected cases of secondary thrombocytopenia acquired autoimmune hemolytic anemia pure red cell aplasia diamond blackfan anemia 7 neoplastic diseases for the treatment of acute leukemia and aggressive lymphomas in adults and children 8 nervous system acute exacerbations of multiple sclerosis 9 ophthalmic diseases uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids temporal arteritis sympathetic ophthalmia 1 respiratory diseases symptomatic sarcoidosis idiopathic eosinophilic pneumonias fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy asthma as distinct from allergic asthma listed above under allergic states hypersensitivity pneumonitis idiopathic pulmonary fibrosis acute exacerbations of chronic obstructive pulmonary disease copd and pneumocystis carinii pneumonia pcp associated with hypoxemia occurring in an hiv individual who is also under treatment with appropriate anti pcp antibiotics studies support the efficacy of systemic corticosteroids for the treatment of these conditions allergic bronchopulmonary aspergillosis idiopathic bronchiolitis obliterans with organizing pneumonia 11 rheumatic disorders as adjunctive therapy for short term administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require low dose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis epicondylitis for the treatment of systemic lupus erythematosus dermatomyositis polymyositis polymyalgia rheumatica sjogren s syndrome relapsing polychondritis and certain cases of vasculitis 12 miscellaneous tuberculous meningitis with subarachnoid block or impending block tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty and tuberculosis with pleural or pericardial effusion appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications trichinosis with neurologic or myocardial involvement acute or chronic solid organ rejection with or without other agents" assertion.
• association label "to reduce the development of drug resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below rocky mountain spotted fever typhus fever and the typhus group q fever rickettsialpox and tick fevers caused by rickettsiae respiratory tract infections caused by lymphogranuloma venereum due to psittacosis ornithosis due to trachoma due to although the infectious agent is not always eliminated as judged by immunofluorescence inclusion conjunctivitis caused by nongonococcal urethritis in adults caused by or relapsing fever due to chancroid caused by plague due to tularemia due to cholera caused by campylobacter fetus infections caused by brucellosis due to species in conjunction with streptomycin bartonellosis due to granuloma inguinale caused by demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug species species respiratory tract infections caused by respiratory tract and urinary tract infections caused by species demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug upper respiratory infections caused by pneumoniae skin and skin structure infections caused by note tetracyclines including demeclocycline are not the drugs of choice in the treatment of any type of staphylococcal infection when penicillin is contraindicated tetracyclines including demeclocycline hydrochloride are alternative drugs in the treatment of the following infections uncomplicated urethritis in men due to and for the treatment of other uncomplicated gonococcal infections infections in women caused by syphilis caused by subspecies yaws caused by subspecies listeriosis due to anthrax due to vincent s infection caused by actinomycosis caused by clostridial diseases caused by species in acute intestinal amebiasis demeclocycline hydrochloride may be a useful adjunct to amebicides in severe acne demeclocycline hydrochloride may be a useful adjunctive therapy mycoplasma pneumoniae chlamydia trachomatis chlamydia psittaci chlamydia trachomatis chlamydia trachomatis ureaplasma urealyticum chlamydia trachomatis borrelia recurrentis haemophilus ducreyi yersinia pestis francisella tularensis vibrio cholerae campylobacter fetus brucella bartonella bacilliformis calymmatobacterium granulomatis escherichia coli enterobacter aerogenes shigella acinetobacter haemophilus influenzae klebsiella streptococcus staphylococcus aureus neisseria gonorrhoeae neisseria gonorrhoeae treponema pallidum pallidum treponema pallidum pertenue listeria monocytogenes bacillus anthracis fusobacterium fusiforme actinomyces israelii clostridium" assertion.
• association label "desmopressin acetate injection is indicated for patients with hemophilia a with factor viii coagulant activity levels greater than 5 desmopressin acetate injection will often maintain hemostasis in patients with hemophilia a during surgical procedures and postoperatively when administered 3 minutes prior to scheduled procedure desmopressin acetate injection will also stop bleeding in hemophilia a patients with episodes of spontaneous or trauma induced injuries such as hemarthroses intramuscular hematomas or mucosal bleeding desmopressin acetate injection is not indicated for the treatment of hemophilia a with factor viii coagulant activity levels equal to or less than 5 or for the treatment of hemophilia b or in patients who have factor viii antibodies in certain clinical situations it may be justified to try desmopressin acetate injection in patients with factor viii levels between 2 to 5 however these patients should be carefully monitored desmopressin acetate injection is indicated for patients with mild to moderate classic von willebrand s disease type i with factor viii levels greater than 5 desmopressin acetate injection will often maintain hemostasis in patients with mild to moderate von willebrand s disease during surgical procedures and postoperatively when administered 3 minutes prior to the scheduled procedure desmopressin acetate injection will usually stop bleeding in mild to moderate von willebrand s patients with episodes of spontaneous or trauma induced injuries such as hemarthroses intramuscular hematomas or mucosal bleeding those von willebrand s disease patients who are least likely to respond are those with severe homozygous von willebrand s disease with factor viii coagulant activity and factor viii von willebrand factor antigen levels less than 1 other patients may respond in a variable fashion depending on the type of molecular defect they have bleeding time and factor viii coagulant activity ristocetin cofactor activity and von willebrand factor antigen should be checked during administration of desmopressin acetate injection to ensure that adequate levels are being achieved desmopressin acetate injection is not indicated for the treatment of severe classic von willebrand s disease type i and when there is evidence of an abnormal molecular form of factor viii antigen see warnings desmopressin acetate injection 4 mcg per ml is indicated as antidiuretic replacement therapy in the management of central cranial diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region desmopressin acetate injection is ineffective for the treatment of nephrogenic diabetes insipidus acetate injection is also available as an intranasal preparation however this means of delivery can be compromised by a variety of factors that can make nasal insufflation ineffective or inappropriate these include poor intranasal absorption nasal congestion and blockage nasal discharge atrophy of nasal mucosa and severe atrophic rhinitis intranasal delivery may be inappropriate where there is an impaired level of consciousness in addition cranial surgical procedures such as transsphenoidal hypophysectomy create situations where an alternative route of administration is needed as in cases of nasal packing or recovery from surgery" assertion.
• association label "paliperidone is an atypical antipsychotic agent indicated for treatment of schizophrenia 1 1 adults efficacy was established in three 6 week trials and one maintenance trial 14 1 adolescents ages 12 to 17 efficacy was established in one 6 week trial 14 1 treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and or antidepressants 1 2 efficacy was established in two 6 week trials in adult patients 14 2 paliperidone extended release tablets are indicated for the treatment of schizophrenia see clinical studies 14 1 the efficacy of paliperidone in schizophrenia was established in three 6 week trials in adults and one 6 week trial in adolescents as well as one maintenance trial in adults paliperidone extended release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and or antidepressant therapy see clinical studies 14 2 the efficacy of paliperidone in schizoaffective disorder was established in two 6 week trials in adults" assertion.
• association label "hydrocortisone tablets usp are indicated in the following conditions endocrine disorders primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer rheumatic disorders as adjunctive therapy for short term administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require low dose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post traumatic osteoarthritis synovitis of osteoarthritis epicondylitis collagen diseases during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis dermatologic diseases pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevens johnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions ophthalmic diseases severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia respiratory diseases symptomatic sarcoidosis loeffler s syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis hematologic disorders idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia neoplastic diseases for palliative management of leukemias and lymphomas in adults acute leukemia of childhood edematous states to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus gastrointestinal diseases to tide the patient over a critical period of the disease in ulcerative colitis regional enteritis nervous system acute exacerbations of multiple sclerosis miscellaneous tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement" assertion.
• association label "vinblastine sulfate injection is indicated in the palliative treatment of the following i frequently responsive malignancies generalized hodgkin s disease stages iii and iv ann arbor modification of rye staging system lymphocytic lymphoma nodular and diffuse poorly and well differentiated histiocytic lymphoma mycosis fungoides advanced stages advanced carcinoma of the testis kaposi s sarcoma letterer siwe disease histiocytosis x ii less frequently responsive malignancies choriocarcinoma resistant to other chemotherapeutic agents carcinoma of the breast unresponsive to appropriate endocrine surgery and hormonal therapy current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents for enhanced therapeutic effect without additive toxicity agents with different dose limiting clinical toxicities and different mechanisms of action are generally selected therefore although vinblastine sulfate is effective as a single agent in the aforementioned indications it is usually administered in combination with other antineoplastic drugs such combination therapy produces a greater percentage of response than does a single agent regimen these principles have been applied for example in the chemotherapy of hodgkin s disease vinblastine sulfate has been shown to be one of the most effective single agents for the treatment of hodgkin s disease advanced hodgkin s disease has also been successfully treated with several multiple drug regimens that included vinblastine sulfate patients who had relapses after treatment with the mopp program mechlorethamine hydrochloride nitrogen mustard vincristine sulfate prednisone and procarbazine have likewise responded to combination drug therapy that included vinblastine sulfate a protocol using cyclophosphamide in place of nitrogen mustard and vinblastine sulfate instead of vincristine sulfate is an alternative therapy for previously untreated patients with advanced hodgkin s disease advanced testicular germinal cell cancers embryonal carcinoma teratocarcinoma and choriocarcinoma are sensitive to vinblastine sulfate alone but better clinical results are achieved when vinblastine sulfate is administered concomitantly with other antineoplastic agents the effect of bleomycin is significantly enhanced if vinblastine sulfate is administered six to eight hours prior to the administration of bleomycin this schedule permits more cells to be arrested during metaphase the stage of the cell cycle in which bleomycin is active" assertion.
• association label "to reduce the development of drug resistant bacteria and maintain the effectiveness of neomycin sulfate tablets and other antibacterial drugs neomycin sulfate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy suppression of intestinal bacteria neomycin sulfate tablets are indicated as adjunctive therapy as part of a regimen for the suppression of the normal bacterial flora of the bowel e g preoperative preparation of the bowel it is given concomitantly with erythromycin enteric coated base see dosage and administration hepatic coma portal systemic encephalopathy neomycin sulfate has been shown to be effective adjunctive therapy in hepatic coma by reduction of the ammonia forming bacteria in the intestinal tract the subsequent reduction in blood ammonia has resulted in neurologic improvement" assertion.
• association label "benazepril hydrochloride tablets usp are indicated for the treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs control of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than one drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education program s joint national committee on prevention detection evaluation and treatment of high blood pressure jnc numerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly elevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal some antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects e g on angina heart failure or diabetic kidney disease these considerations may guide selection of therapy it may be used alone or in combination with thiazide diuretics benazepril hydrochloride tablets usp are an angiotensin converting enzyme ace inhibitor indicated for the treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions 1" assertion.
• association label "itraconazole capsules are indicated for the treatment of the following fungal infections in immunocompromised and non immunocompromised patients 1 blastomycosis pulmonary and extrapulmonary 2 histoplasmosis including chronic cavitary pulmonary disease and disseminated non meningeal histoplasmosis and 3 aspergillosis pulmonary and extrapulmonary in patients who are intolerant of or who are refractory to amphotericin b therapy specimens for fungal cultures and other relevant laboratory studies wet mount histopathology serology should be obtained before therapy to isolate and identify causative organisms therapy may be instituted before the results of the cultures and other laboratory studies are known however once these results become available antiinfective therapy should be adjusted accordingly itraconazole capsules are also indicated for the treatment of the following fungal infections in non immunocompromised patients 1 onychomycosis of the toenail with or without fingernail involvement due to dermatophytes tinea unguium and 2 onychomycosis of the fingernail due to dermatophytes tinea unguium prior to initiating treatment appropriate nail specimens for laboratory testing koh preparation fungal culture or nail biopsy should be obtained to confirm the diagnosis of onychomycosis see clinical pharmacology special populations contraindications warnings adverse reactions post marketing experience description of clinical studies blastomycosis analyses were conducted on data from two open label non concurrently controlled studies n 73 combined in patients with normal or abnormal immune status the median dose was 2 mg day a response for most signs and symptoms was observed within the first 2 weeks and all signs and symptoms cleared between 3 and 6 months results of these two studies demonstrated substantial evidence of the effectiveness of itraconazole for the treatment of blastomycosis compared with the natural history of untreated cases histoplasmosis analyses were conducted on data from two open label non concurrently controlled studies n 34 combined in patients with normal or abnormal immune status not including hiv infected patients the median dose was 2 mg day a response for most signs and symptoms was observed within the first 2 weeks and all signs and symptoms cleared between 3 and 12 months results of these two studies demonstrated substantial evidence of the effectiveness of itraconazole for the treatment of histoplasmosis compared with the natural history of untreated cases histoplasmosis in hiv infected patients data from a small number of hiv infected patients suggested that the response rate of histoplasmosis in hiv infected patients is similar to that of non hiv infected patients the clinical course of histoplasmosis in hiv infected patients is more severe and usually requires maintenance therapy to prevent relapse aspergillosis analyses were conducted on data from an open label single patient use protocol designed to make itraconazole available in the u s for patients who either failed or were intolerant of amphotericin b therapy n 19 the findings were corroborated by two smaller open label studies n 31 combined in the same patient population most adult patients were treated with a daily dose of 2 to 4 mg with a median duration of 3 months results of these studies demonstrated substantial evidence of effectiveness of itraconazole as a second line therapy for the treatment of aspergillosis compared with the natural history of the disease in patients who either failed or were intolerant of amphotericin b therapy onychomycosis of the toenail analyses were conducted on data from three double blind placebo controlled studies n 214 total 11 given itraconazole capsules in which patients with onychomycosis of the toenails received 2 mg of itraconazole capsules once daily for 12 consecutive weeks results of these studies demonstrated mycologic cure defined as simultaneous occurrence of negative koh plus negative culture in 54 of patients thirty five percent 35 of patients were considered an overall success mycologic cure plus clear or minimal nail involvement with significantly decreased signs and 14 of patients demonstrated mycologic cure plus clinical cure clearance of all signs with or without residual nail deformity the mean time to overall success was approximately 1 months twenty one percent 21 of the overall success group had a relapse worsening of the global score or conversion of koh or culture from negative to positive onychomycosis of the fingernail analyses were conducted on data from a double blind placebo controlled study n 73 total 37 given itraconazole capsules in which patients with onychomycosis of the fingernails received a 1 week course of 2 mg of itraconazole capsules b i d followed by a 3 week period without itraconazole which was followed by a second 1 week course of 2 mg of itraconazole capsules b i d results demonstrated mycologic cure in 61 of patients fifty six percent 56 of patients were considered an overall success and 47 of patients demonstrated mycologic cure plus clinical cure the mean time to overall success was approximately 5 months none of the patients who achieved overall success relapsed" assertion.
• association label "nuvigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea osa narcolepsy or shift work disorder swd in osa nuvigil is indicated to treat excessive sleepiness and not as treatment for the underlying obstruction if continuous positive airway pressure cpap is the treatment of choice for a patient a maximal effort to treat with cpap for an adequate period of time should be made prior to initiating nuvigil for excessive sleepiness if nuvigil is used adjunctively with cpap the encouragement of and periodic assessment of cpap compliance is necessary in all cases careful attention to the diagnosis and treatment of the underlying sleep disorder s is of utmost importance prescribers should be aware that some patients may have more than one sleep disorder contributing to their excessive sleepiness the effectiveness of nuvigil in long term use greater than 12 weeks has not been systematically evaluated in placebo controlled trials the physician who elects to prescribe nuvigil for an extended time in patients should periodically re evaluate long term usefulness for the individual patient nuvigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with treated obstructive sleep apnea osa narcolepsy or shift work disorder swd 1" assertion.
• association label "buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short term relief of the symptoms of anxiety anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic the efficacy of buspirone hydrochloride tablets have been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder gad many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study with an average symptom duration of 6 months generalized anxiety disorder 3 2 is described in the american psychiatric association s diagnostic and statistical manual iii1 as follows generalized persistent anxiety of at least 1 month continual duration manifested by symptoms from three of the four following categories 1 motor tension shakiness jitteriness jumpiness trembling tension muscle aches fatigability inability to relax eyelid twitch furrowed brow strained face fidgeting restlessness easy startle 2 autonomic hyperactivity sweating heart pounding or racing cold clammy hands dry mouth dizziness lightheadedness paresthesias tingling in hands or feet upset stomach hot or cold spells frequent urination diarrhea discomfort in the pit of the stomach lump in the throat flushing pallor high resting pulse and respiration rate 3 apprehensive expectation anxiety worry fear rumination and anticipation of misfortune to self or others 4 vigilance and scanning hyperattentiveness resulting in distractibility difficulty in concentrating insomnia feeling on edge irritability impatience the above symptoms would not be due to another mental disorder such as a depressive disorder or schizophrenia however mild depressive symptoms are common in gad the effectiveness of buspirone hydrochloride tablets in long term use that is for more than 3 to 4 weeks has not been demonstrated in controlled trials there is no body of evidence available that systematically addresses the appropriate duration of treatment for gad however in a study of long term use 264 patients were treated with buspirone hydrochloride tablets for 1 year without ill effect therefore the physician who elects to use buspirone hydrochloride tablets for extended periods should periodically reassess the usefulness of the drug for the individual patient" assertion.
• association label "prednisolone syrup prednisolone oral solution usp is indicated in the following conditions 1 endocrine disorders primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2 rheumatic disorders as adjunctive therapy for short term administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require low dose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post traumatic osteoarthritis synovitis of osteoarthritis epicondylitis 3 collagen diseases during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus acute rheumatic carditis 4 dermatologic diseases pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevens johnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis 5 allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis bronchial asthma contact dermatitis atopic dermatitis serum sickness drug hypersensitivity reactions 6 ophthalmic diseases severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic corneal marginal ulcers herpes zoster ophthalmicus anterior segment inflammation diffuse posterior uveitis and choroiditis sympathetic ophthalmia allergic conjunctivitis keratitis chorioretinitis optic neuritis iritis and iridocyclitis 7 respiratory diseases symptomatic sarcoidosis loeffler s syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate chemotherapy aspiration pneumonitis 8 hematologic disorders idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia 9 neoplastic diseases for palliative management of leukemias and lymphomas in adults acute leukemia of childhood 1 edematous states to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus 11 gastrointestinal diseases to tide the patient over a critical period of the disease in ulcerative colitis regional enteritis 12 miscellaneous tuberculous meningitis with subarachnoid block or impending block used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement in addition to the above indications prednisolone syrup prednisolone oral solution usp is indicated for systemic dermatomyositis polymyositis" assertion.
• association label "gentamicin sulfate ophthalmic solution is indicated in the topical treatment of ocular bacterial infections including conjunctivitis keratitis keratoconjunctivitis corneal ulcers blepharitis blepharoconjunctivitis acute meibomianitis and dacryocystitis caused by susceptible strains of the following microorganisms staphylococcus aureus staphylococcus epidermidis streptococcus pyogenes streptococcus pneumoniae enterobacter aerogenes escherichia coli haemophilus influenzae klebsiella pneumoniae neisseria gonorrhoeae pseudomonas aeruginosa and serratia marcescens" assertion.
• association label "minocycline hydrochloride capsules usp are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms rocky mountain spotted fever typhus fever and the typhus group q fever rickettsialpox and tick fevers caused by rickettsiae respiratory tract infections caused by mycoplasma pneumoniae lymphogranuloma venereum caused by chlamydia trachomatis psittacosis ornithosis due to chlamydia psittaci trachoma caused by chlamydia trachomatis although the infectious agent is not always eliminated as judged by immunofluorescence inclusion conjunctivitis caused by chlamydia trachomatis nongonococcal urethritis endocervical or rectal infections in adults caused by ureaplasma urealyticum or chlamydia trachomatis relapsing fever due to borrelia recurrentis chancroid caused by haemophilus ducreyi plague due to yersinia pestis tularemia due to francisella tularensis cholera caused by vibrio cholerae campylobacter fetus infections caused by campylobacter fetus brucellosis due to brucella species in conjunction with streptomycin bartonellosis due to bartonella bacilliformis granuloma inguinale caused by calymmatobacterium granulomatis minocycline is indicated for the treatment of infections caused by the following gram negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug escherichia coli enterobacter aerogenes shigella species acinetobacter species respiratory tract infections caused by haemophilus influenzae respiratory tract and urinary tract infections caused by klebsiella species minocycline hydrochloride capsules usp are indicated for the treatment of infections caused by the following gram positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug upper respiratory tract infections caused by streptococcus pneumoniae skin and skin structure infections caused by staphylococcus aureus note minocycline is not the drug of choice in the treatment of any type of staphylococcal infection when penicillin is contraindicated minocycline is an alternative drug in the treatment of the following infections uncomplicated urethritis in men due to neisseria gonorrhoeae and for the treatment of other gonococcal infections infections in women caused by neisseria gonorrhoeae syphilis caused by treponema pallidum subspecies pallidum yaws caused by treponema pallidum subspecies pertenue listeriosis due to listeria monocytogenes anthrax due to bacillus anthracis vincent s infection caused by fusobacterium fusiforme actinomycosis caused by actinomyces israelii infections caused by clostridium species in acute intestinal amebiasis minocycline may be a useful adjunct to amebicides in severe acne minocycline may be useful adjunctive therapy oral minocycline is indicated in the treatment of asymptomatic carriers of neisseria meningitidis to eliminate meningococci from the nasopharynx in order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers diagnostic laboratory procedures including serotyping and susceptibility testing should be performed to establish the carrier state and the correct treatment it is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high oral minocycline is not indicated for the treatment of meningococcal infection although no controlled clinical efficacy studies have been conducted limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by mycobacterium marinum to reduce the development of drug resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules usp and other antibacterial drugs minocycline hydrochloride capsules usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy close" assertion.
• association label "nadolol tablets usp are indicated for the long term management of patients with angina pectoris nadolol tablets usp are indicated for the treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs there are no controlled trials demonstrating risk reduction with nadolol tablets usp control of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than one drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education program s joint national committee on prevention detection evaluation and treatment of high blood pressure jnc numerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly elevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal some antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects e g on angina heart failure or diabetic kidney disease these considerations may guide selection of therapy nadolol tablets usp may be used alone or in combination with other antihypertensive agents especially thiazide type diuretics" assertion.
• integrin-clustering label "integrin clustering" assertion.
• spi label "Increased glycocalyx bulk mechanically drives integrin clustering" assertion.
• spi label "Glycocalyx bulk mechanically drives integrin clustering in cancer cells engaged with the extracellular matrix" assertion.

• first
• previous
• next